Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

AscellaHealth Launches Q2 2025 Specialty & Rare Pipeline Digest™ to Support Stakeholders Navigating Specialty Drug Growth

AH_2025Q2_PipelineDigest_063025.2 3

BERWYN, Pa., July 10, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, announces the release of its Q2 2025 Specialty & Rare Pipeline Digest™. As the industry’s most comprehensive digital resource, this complimentary quarterly publication provides stakeholders with critical, up-to-date information on new, pending and upcoming specialty and rare disease drug launches and approvals, biosimilars and cell and gene therapies (CGTs). Designed to support stakeholders amid the accelerating pace of specialty drug approvals, the Digest delivers timely insights that enable proactive management and strategic utilization of emerging therapies.

"The continued acceleration of specialty and rare drug development – with over a dozen new approvals in Q2 alone – highlights the critical need for a comprehensive resource that helps industry stakeholders stay ahead of evolving market dynamics,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “Our dedicated team of clinical researchers and expert data analysts meticulously develops this robust digest to provide manufacturers, payers and providers with actionable intelligence that supports strategic decision-making and, ultimately, enhances patient outcomes.”

Q2 2025 Highlights: Growth in Specialty and CGT Approvals
The second quarter of 2025 witnessed an uptick in the volume of newly approved branded specialty medications, reflecting the FDA’s ongoing commitment to expediting access to therapies for complex diseases. Among these, CGTs continue to demonstrate strong momentum, with Q2 marking several important milestones in the treatment of rare and serious conditions. Both recent approvals and therapies under regulatory review highlight the expanding potential of CGTs to transform care and improve outcomes for patients with limited treatment options.

Looking Ahead: 2025–2026 Outlook
The specialty drug pipeline is projected to experience steady growth through 2026, with a continued emphasis on orphan drugs and CGTs. Specialty medications are expected to account for more than half of total drug spending during this period, reflecting their increasing role in addressing complex conditions. Currently, 71% of new drug submissions are classified as specialty, and 34% carry orphan drug designation—highlighting the industry’s sustained focus on delivering innovative treatments for underserved patient populations.

Read more findings in the latest Specialty & Rare Pipeline Digest™ here.

About AscellaHealth LLC
AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. For more information on our services and solutions, visit www.AscellaHealth.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/da3fd58d-acbe-4e8e-a2a2-c42a0ace8c2d

This press release was published by a CLEAR® Verified individual.


Media:

Caroline Chambers
CPR Communications
cchambers@cpronline.com
201.641.1911 x 21

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.